OTCMKTS:VBIO

Vitality Biophar Stock Predictions

Healthcare > Biotechnology

Buy VBIO

*Your capital is at risk

$0.310

+0.0320 (+11.51%)

At Close: Jul 31, 2026

Currently predicting for Mon, 3 Aug 2026

VBIO Live board

Community Bull/Bear

Target Next close

Join the VBIO prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

VBIO Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For VBIO

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

VBIO Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT VITALITY BIOPHAR

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of inflammatory disorders in the United States. The company is developing tetrahydrocannabinol glycoside (VBX-100), an oral cannabinoid prodrug for inflammatory bowel disease and irritable bowel syndromes. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. wa...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
FOX $50.81	2.22%	Jul 27
UNFI $49.05	3.63%	Jul 27
BIIB $202.19	0.376%	Jul 24
TSCO $30.32	1.48%	Jul 23
S SW $43.71	5.17%	Jul 23

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by